

BONE MARROW TRANSPLANT REFERRAL FORM

PATIENT INFORMATION (please attach insurance card)

Name:		☐ M ☐ F	DoB:	
Street:		City:		State: Zip:
Phone:	Phone:	Allergies:		

CLINICAL INFORMATION (please attach clinical notes and labs)

Diagnosis with ICD-10 code
☐ **B25.9** cytomegalovirus (CMV) prophylaxis and/or treatment
 ☐ **D89.813** graft-versus-host disease (GVHD)
 ☐ **B44.9** *Aspergillus* (circle one) prophylaxis/treatment
 ☐ Other: _____
 ☐ **K76.5** prevention of hepatic sinusoidal obstruction syndrome associated with stem cell transplant

height: _____ **weight:** _____ kg
 Labs (please attach most recent results): ☐ CMP ☐ CMV level

Current medication(s) with date(s) started: _____
 Prior medication(s) with date(s) of use: _____

PRESCRIPTION

☐ **DAW** (deliver to ☐ patient ☐ office)

Medication	Dose/Strength	Directions/Sig	Quantity	Refills
☐ cyclosporine, modified (Gengraf, Neoral)	Caps: ☐ 25mg ☐ 50mg ☐ 100mg Soln: ☐ 100mg/mL			
☐ cyclosporine, non-modified (SandIMMUNE)	Caps: ☐ 25mg ☐ 50mg ☐ 100mg Soln: ☐ 100mg/mL			
☐ tacrolimus	Caps: ☐ 0.5mg ☐ 1mg ☐ 5mg			
☐ ursodiol	Caps: ☐ 200mg ☐ 300mg ☐ 400mg Tabbs: ☐ 250mg ☐ 500mg			

Prophylaxis and/or Treatment, *Aspergillus*

☐ Cresemba	Caps: ☐ 74.5mg ☐ 186mg	☐ Initiation: 372mg PO Q8h x 6 doses ☐ Maintenance: 372mg PO once daily		
☐ posaconazole	Susp: ☐ 40mg/mL Tabbs: ☐ 100mg			
☐ voriconazole	Susp: ☐ 40mg/mL Tabbs: ☐ 50mg ☐ 200mg			

Prophylaxis and/or Treatment, CMV

☐ Livtency	200mg tablet	400mg PO twice daily for _____ weeks		
☐ Prevymis	Tabbs: ☐ 240mg ☐ 480mg	_____mg PO once daily for _____ weeks		
☐ valganciclovir	Tabbs: ☐ 500mg ☐ 1g			
☐ valganciclovir (Valcyte)	Soln: ☐ 50mg/mL Tabbs: ☐ 450mg			
Other:				

PRESCRIBER INFORMATION

Prescriber:		Supervising Physician:	
Contact Name:	Contact Method: ☐ Phone ☐ Fax ☐ Email:		
Phone:	Ext:	Fax:	
Street:	City:	State:	Zip:
Signature:	Date:	NPI:	

BONE MARROW TRANSPLANT REFERRAL FORM (GCSF)

Phone: 404-585-7517
Fax: 404-900-9209
NPI: 1811550528
synergengerx.com

PATIENT INFORMATION (please attach insurance card)

Name:		☐ M ☐ F	DoB:	
Street:		City:		State: Zip:
Phone:	Phone:	Allergies:		

CLINICAL INFORMATION (please attach clinical notes and labs)

Diagnosis with ICD-10 code	☐ C92.A0 acute myeloid leukemia following induction or consolidation chemotherapy	height: _____
	☐ D75.9 chemotherapy-induced myelosuppression in nonmyeloid malignancies	
	☐ D46.9 myelodysplastic syndromes with anemia	weight: _____ kg
	☐ D61.03 Fanconi anemia-associated neutropenia	
☐ D70.1 prevention of chemotherapy-induced neutropenia		Labs (please attach most recent results): ☐ CBC with differential ☐ ANC: _____ cells/mcL
☐ D70.9 severe chronic neutropenia		
☐ T66.XXXA hematopoietic radiation injury syndrome, acute		
☐ Z94.81 bone marrow transplantation		
☐ Z94.84 hematopoietic cell mobilization for apheresis collection		
☐ Other: _____		

Current medication(s) with date(s) started: _____
Prior medication(s) with date(s) of use: _____

PRESCRIPTION

☐ **DAW** (deliver to ☐ patient ☐ office)

Medication	Dose/Strength	Directions/Sig	Quantity	Refills
☐	Check this box to authorize the pharmacy to interchange to the plan's preferred biosimilar if needed			
☐ Granix (tbo-filgrastim)	PFS: ☐ 300mcg/0.5mL ☐ 480mcg/0.8mL Soln: ☐ 300mcg/mL ☐ 480mcg/1.6mL			
☐ Nivestym (filgrastim)	PFS: ☐ 300mcg/0.5mL ☐ 480mcg/0.8mL Soln: ☐ 300mcg/mL ☐ 480mcg/1.6mL			
☐ Releuko (filgrastim)	PFS: ☐ 300mcg/0.5mL ☐ 480mcg/0.8mL Soln: ☐ 300mcg/mL ☐ 480mcg/1.6mL			

Pegfilgrastim (extended interval)

☐ Fulphila	6mg/0.6mL PFS			
☐ Fylnetra	6mg/0.6mL PFS			
☐ Nyvepria	6mg/0.6mL PFS			
☐ Udenyca	Pen: ☐ 6mg/0.6mL PFS: ☐ 6mg/0.6mL			

Ancillary

☐ alcohol swabs	use to clean injection site prior to each injection		
☐ sharps container	use to dispose of syringes after each injection	1	
Other:			

PRESCRIBER INFORMATION

Prescriber:		Supervising Physician:	
Contact Name:	Contact Method: ☐ Phone ☐ Fax ☐ Email:		
Phone:	Ext:	Fax:	
Street:	City:	State:	Zip:
Signature:	Date:	NPI:	

*By signing this form, I authorize Synergen Rx LLC and its employees to act as authorized agents on behalf of my office to obtain prior authorization through my patient's insurance plan and to facilitate the enrollment of the patient into patient assistance programs with manufacturers and other foundations.